Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to read an analysis of NVAX stock now.

In a move to bolster its drug manufacturing capabilities in the United States, Thermo Fisher has purchased a sterile fill-finish and packaging plant from Sanofi in Ridgefield, New Jersey.

Astra, led by boss Pascal Soriot (pictured), said it is accelerating its expansion in US with an investment that will create ...

Casper claimed that during the quarter, Thermo Fisher advanced its growth strategy, launching a range of high-impact ...

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...

AstraZeneca said the expansion supports its ambition to reach $80 billion in annual revenue by 2030, with half coming from ...

The company's net profit is expected to come at ₹1,460 crore, marking around 4.9 per cent Y-o-Y increase, on average, as ...

AstraZeneca on Monday announced plans to invest $50 billion in its US operations by 2030, a sweeping commitment that includes ...

Premature babies in the UK can now be protected against RSV with a single, long-lasting injection available on the NHS for ...

AstraZeneca plans a $50bn investment in US manufacturing and R&D by 2030, responding to Trump’s tariff threats and signalling ...

Quarterly pharmaceutical sales surpassed $15 billion for the first time as strong performance from J&J's cancer medicines offset slumping Stelara sales.